Study of RP3 Monotherapy and RP3 in Combination With Anti-PD1 Therapy in Patients With Solid Tumours
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Advanced Solid Tumor
- Type
- Interventional
- Phase
- Phase 1
- Design
- Allocation: Non-RandomizedIntervention Model: Sequential AssignmentIntervention Model Description: Part 1 - Dose Escalation - Participants will be enrolled into two sequential dose level cohorts. Part 2 - Dose Combination - Participants will receive a fixed dose of RP3 in combination with anti-PD1 therapy.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
RP3 is a genetically modified herpes simplex type 1 virus (HSV-1) that expresses exogenous genes (anti-CTLA-4 antibody, CD40 ligand and h4-1BBL) designed to directly destroy tumors and generate an anti-tumor immune response
RP3 is a genetically modified herpes simplex type 1 virus (HSV-1) that expresses exogenous genes (anti-CTLA-4 antibody, CD40 ligand and h4-1BBL) designed to directly destroy tumors and generate an anti-tumor immune response
Tracking Information
- NCT #
- NCT04735978
- Collaborators
- Not Provided
- Investigators
- Study Director: Henry Castro, MD Replimune Inc.
Get Well Soon